INC Research Holdings, Inc. (NASDAQ:INCR) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday.

According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “

A number of other equities research analysts have also weighed in on INCR. BidaskClub lowered INC Research Holdings from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Jefferies Group LLC restated a “hold” rating and set a $62.50 price objective on shares of INC Research Holdings in a research report on Sunday, July 30th. TheStreet lowered INC Research Holdings from a “b” rating to a “c” rating in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $65.00 price objective on shares of INC Research Holdings in a research report on Monday, August 7th. Finally, Mizuho initiated coverage on INC Research Holdings in a research report on Thursday, September 21st. They set a “neutral” rating and a $57.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $56.33.

Shares of INC Research Holdings (NASDAQ:INCR) opened at $37.75 on Thursday. The firm has a market capitalization of $3,970.00 and a price-to-earnings ratio of 15.76. INC Research Holdings has a 52-week low of $33.60 and a 52-week high of $61.10. The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.99.

INC Research Holdings (NASDAQ:INCR) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.63 by ($0.09). The firm had revenue of $592.21 million for the quarter, compared to the consensus estimate of $604.95 million. INC Research Holdings had a positive return on equity of 14.42% and a negative net margin of 4.29%. The company’s revenue was up 128.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 EPS. analysts forecast that INC Research Holdings will post 2.29 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/18/zacks-investment-research-downgrades-inc-research-holdings-inc-incr-to-strong-sell.html.

In other INC Research Holdings news, CFO Gregory S. Rush sold 9,703 shares of INC Research Holdings stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $54.48, for a total transaction of $528,619.44. Following the transaction, the chief financial officer now directly owns 78,593 shares of the company’s stock, valued at approximately $4,281,746.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Christopher L. Gaenzle sold 4,682 shares of INC Research Holdings stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $54.56, for a total value of $255,449.92. Following the transaction, the chief accounting officer now directly owns 60,579 shares in the company, valued at $3,305,190.24. The disclosure for this sale can be found here. Insiders have sold a total of 189,493 shares of company stock worth $11,059,514 over the last ninety days. Company insiders own 0.24% of the company’s stock.

Several large investors have recently made changes to their positions in INCR. Principal Financial Group Inc. lifted its stake in shares of INC Research Holdings by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 44,821 shares of the company’s stock valued at $2,055,000 after purchasing an additional 1,154 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of INC Research Holdings by 20.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 776,389 shares of the company’s stock valued at $35,597,000 after purchasing an additional 134,313 shares during the period. BlackRock Inc. lifted its stake in shares of INC Research Holdings by 40,517.6% in the 1st quarter. BlackRock Inc. now owns 3,544,294 shares of the company’s stock valued at $162,506,000 after purchasing an additional 3,535,568 shares during the period. State Street Corp lifted its stake in shares of INC Research Holdings by 0.8% in the 1st quarter. State Street Corp now owns 831,489 shares of the company’s stock valued at $38,126,000 after purchasing an additional 6,742 shares during the period. Finally, Capstone Asset Management Co. acquired a new position in shares of INC Research Holdings in the 2nd quarter valued at about $456,000. 77.75% of the stock is currently owned by institutional investors.

INC Research Holdings Company Profile

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Analyst Recommendations for INC Research Holdings (NASDAQ:INCR)

Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.